Fitness companies could develop evidence-based protocols tailored to GLP-1 users at different stages of treatment
An analysis by the Annals of Internal Medicine published in October 2022 found that the price of GLP-1s would need to drop by 90% to be considered reasonable for use as a first-line therapy
Rather, it is a benchmark rate that is based on the general trend toward increasing rates of sustained virologic response in recent years and the general appeal of using a fixed, clinically relevant threshold as a measure of treatment benefit.16 We determined that the enrollment of 500 patients in the sofosbuvir-velpatasvir group would provide a power of 90% to detect an improvement of at least 5 percentage points in the rate of sustained virologic response over the performance goal of 85%, on the basis of the two-sided exact one-sample binomial test at the 0.05 significance level
de Bengy, A.-F., Decorps, J., Martin, L
Patients can learn more about outside financing options on the financing page
Lancet 2022;399:394-405.ArticlePubMed 31